Jacob Saya L, Cornell Erika, Kwa Michael, Funk William E, Xu Shuai
Northwestern University Feinberg School of Medicine, Chicago, IL.
Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine.
JNCI Cancer Spectr. 2018 Jun 20;2(2):pky012. doi: 10.1093/jncics/pky012. eCollection 2018 Apr.
There have been numerous controversies surrounding cosmetic products and increased cancer risk. Such controversies include associations between parabens and breast cancer, hair dyes and hematologic malignancies, and talc powders and ovarian cancer. Despite the prominent media coverage and numerous scientific investigations, the majority of these associations currently lack conclusive evidence. In 2016, the US Food and Drug Administration (FDA) made publically available all adverse event reports in Center for Food Safety and Applied Nutrition's Adverse Event Reporting System (CAERS), which includes complaints related to cosmetic products. We mined CAERS for cancer-related reports attributed to cosmetics. Between 2004 and 2017, cancer-related reports caused by cosmetics represented 41% of all adverse events related to cosmetics. This yielded 4427 individual reports of cancer related to a cosmetic product. Of these reports, the FDA redacted the specific product names in 95% of cancer-related reports under the Freedom of Information Act exemptions, most likely due to ongoing legal proceedings. For redacted reports, ovarian cancer reports dominated (n = 3992, 90%), followed by mesothelioma (n = 92, 2%) and malignant neoplasm unspecified (n = 46, 1%). For nonredacted reports, or those reports whose product names were not withheld (n = 218), 70% were related to ovarian cancer attributed to talc powders, followed by skin cancer (11%) and breast cancer (5%) attributed to topical moisturizers. Currently, CAERS is of limited utility, with the available data having been subjected to significant reporter bias and a lack of supportive information such as demographic data, medical history, or concomitant product use. Although the system has promise for safeguarding public health, the future utility of the database requires broader reporting participation and more complete reporting, paired with parallel investments in regulatory science and improved molecular methods.
围绕化妆品及癌症风险增加存在众多争议。此类争议包括对羟基苯甲酸酯与乳腺癌、染发剂与血液系统恶性肿瘤、滑石粉与卵巢癌之间的关联。尽管媒体对此进行了大量报道且有众多科学调查,但目前这些关联大多缺乏确凿证据。2016年,美国食品药品监督管理局(FDA)公开了食品安全与应用营养中心不良事件报告系统(CAERS)中的所有不良事件报告,其中包括与化妆品相关的投诉。我们在CAERS中挖掘归因于化妆品的癌症相关报告。2004年至2017年期间,由化妆品导致的癌症相关报告占所有与化妆品相关不良事件的41%。这产生了4427份与化妆品相关的癌症个体报告。在这些报告中,根据《信息自由法》豁免条款,FDA在95%的癌症相关报告中对具体产品名称进行了编辑,最有可能是由于正在进行的法律诉讼。对于编辑后的报告,卵巢癌报告占主导(n = 3992,90%),其次是间皮瘤(n = 92,2%)和未明确的恶性肿瘤(n = 46,1%)。对于未编辑的报告,即那些产品名称未被隐瞒的报告(n = 218),70%与滑石粉导致的卵巢癌有关,其次是皮肤癌(11%)和局部保湿剂导致的乳腺癌(5%)。目前,CAERS的效用有限,现有数据存在显著的报告偏差,且缺乏诸如人口统计学数据、病史或同时使用的产品等支持性信息。尽管该系统有望保障公众健康,但数据库的未来效用需要更广泛的报告参与和更完整的报告,同时需要在监管科学和改进分子方法方面进行并行投资。